A clinical study reports that circulating REG1B and REG3G are elevated in patients diagnosed with atherosclerosis and correlate with disease severity, including an association for REG1B with distinguishing early non-obstructive disease. The findings position these proteins as candidate blood-based markers that could help refine risk detection beyond traditional imaging and lipid metrics. The work describes statistically significant elevations of both biomarkers in atherosclerosis patients, with REG1B proposed as the more discriminative signal for earlier stages, while REG3G tracks with overall severity. The study’s design emphasizes biomarker utility as a potential adjunct for earlier stratification. From a development standpoint, the key translational value is the possibility of non-invasive monitoring for vascular disease state and progression using small-molecule or immunoassay-accessible targets. Further validation would be needed before clinical use, but the signal supports continued biomarker discovery focused on early atherosclerosis biology rather than only advanced plaque disease.